Anticoagulation in preterm and term neonates: Why are they special?

Rukhmi Bhat*, Paul Monagle

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

The preterm and term neonatal population is most at risk for thrombotic complications in pediatrics. Among various treatment modalities, anticoagulation is primarily used in the management of thrombosis. Developmental differences in preterm and term infants compared to older infants and children and limitations of anticoagulation agents currently used are important considerations for treatment. Additionally, dosages and durations of anticoagulant treatment are widely variable across countries. This article will highlight the differences in anticoagulation in neonates compared to other populations due to developmental hemostatic changes, epidemiology of neonatal thrombosis, pharmacokinetic and pharmacodynamic properties of drugs used and presence of neonatal co-morbidities.

Original languageEnglish (US)
Pages (from-to)113-121
Number of pages9
JournalThrombosis research
Volume187
DOIs
StatePublished - Mar 2020

Keywords

  • Anticoagulation
  • Neonate
  • Pediatrics
  • Preterm
  • Thrombosis

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Anticoagulation in preterm and term neonates: Why are they special?'. Together they form a unique fingerprint.

  • Cite this